
Reduced Dose of Abiraterone Acetate with Concomitant Low-dose Prednisone in the Treatment of ≥85 Year-old Patients with Advanced Castrate-resistant Prostate Cancer.

Petrioli R, Francini E, Fiaschi A, Laera L, Miano ST, DE Rubertis G, Roviello G.

Abstract

AIM: The aim of the study was to evaluate the activity and safety of reduced-dose abiraterone acetate (AA) in ≥85 year-old patients with advanced castrate-resistant prostate cancer (CRPC).

PATIENTS AND METHODS: Patients received 750 mg oral AA as three 250-mg tablets once daily, with concomitant oral prednisone, 5 mg daily.

RESULTS: Twenty-six patients were enrolled; median age was 88 years (range=85-93). Prostate-specific antigen (PSA) response was observed in 18 (69.2%) subjects, median time to PSA progression was 6.4 months (95% confidence interval (CI)=2.8-8.8) and median overall survival was 14.3 months (95% CI=7.2-18.3). The treatment was well-tolerated and adverse events, related to mineralocorticoid excess, were of grade 1-2 in all patients.

CONCLUSION: Reduced dose of AA combined with a very low dose of prednisone is effective and well-tolerated in very elderly patients with advanced CRPC.

Copyright© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

KEYWORDS: Abiraterone; PSA; castrate-resistant; elderly; prostate cancer

PMID: 25964601 [PubMed - in process]